Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
170.99
+0.06 (0.04%)
At close: Aug 6, 2026, 4:00 PM EDT
170.99
0.00 (0.00%)
After-hours: Aug 6, 2026, 4:10 PM EDT
Glaukos Revenue
Glaukos had revenue of $185.61M in the quarter ending June 30, 2026, with 49.54% growth. This brings the company's revenue in the last twelve months to $612.84M, up 41.55% year-over-year. In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth.
Revenue (ttm)
$612.84M
Revenue Growth
+41.55%
P/S Ratio
16.32
Revenue / Employee
$560,182
Employees
1,094
Market Cap
10.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
| Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
| Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
| Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
| Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
| Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
| Dec 31, 2013 | 20.95M | 18.52M | 762.33% |
| Dec 31, 2012 | 2.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| STERIS | 5.94B |
| Bruker | 3.50B |
| Globus Medical | 3.10B |
| Insulet | 3.05B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
GKOS News
- 6 days ago - Glaukos Slides: Investor presentation - Filings
- 7 days ago - Glaukos price target raised to $195 from $168 at H.C. Wainwright - TheFly
- 7 days ago - Glaukos price target raised to $172 from $150 at UBS - TheFly
- 7 days ago - Glaukos price target raised to $193 from $164 at BTIG - TheFly
- 7 days ago - Glaukos price target raised to $201 from $150 at Needham - TheFly
- 7 days ago - Glaukos price target raised to $190 from $175 at Stifel - TheFly
- 7 days ago - Glaukos price target raised to $195 from $165 at Piper Sandler - TheFly
- 7 days ago - Glaukos price target raised to $188 from $175 at Citi - TheFly